Viatris to buy Pacira Biosciences for $1.65 billion, sending shares soaring

Viatris announced it will acquire Pacira Biosciences for $1.65B, triggering a sharp rally in Pacira shares and highlighting ongoing appetite for biotech M&A. The deal can lift risk sentiment within healthcare equities and spark sector rotation into small- and mid-cap biopharma, while focusing attention on funding conditions and strategic buyers' willingness to deploy capital.